Cardiac remodeling in coronary artery disease

American Journal of Cardiology

Volumn 93, Issue 9 SUPPL. 1, 2004, Pages 17-20

  Sharpe, Norman ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; PLACEBO;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG TARGETING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 2442564649     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.01.002     Document Type: Article

References (22)

1. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction pathophysiology and therapy. Circulation. 101:2000;2981-2988
2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582
3. Sharpe D.N., Murphy J., Coxon R., Hannan S.F. Enalapril in patients with chronic heart failure a placebo-controlled, randomized, double-blind study. Circulation. 70:1984;271-278
4. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure: SOLVD Investigators. Circulation 1992;86:431-438
5. Greenberg B., Quinones M.A., Koilpillai C., Limacher M., Shindler D., Benedict C., Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction results of the SOLVD echocardiography substudy. Circulation. 91:1995;2573-2581
6. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1:1988;255-259
7. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 319:1988;80-86
8. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 337:1991;872-876
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677
10. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-828
11. Yue T.L., Ma X.L., Wang X., Romanic A.M., Liu G.L., Louden C., Gu J.L., Kumar S., Poste G., Ruffolo R.R. Jr, Feuerstein G.Z. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 82:1998;166-174
12. Wei S., Chow L.T., Sanderson J.E. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol. 36:2000;276-281
13. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction a placebo-controlled, randomized trial. Circulation. 96:1997;183-191
14. Senior R., Basu S., Kinsey C., Schaeffer S., Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J. 137:1999;646-652
15. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390
16. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N, on behalf of the CAPRICORN Echo Substudy investigators. Effects of carvedilol on left ventricular remodeling following acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-206
17. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218
18. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-380
19. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066
20. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996;94:2807-2816
21. Basu S., Senior R., Raftery E.B., Lahiri A. The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. Eur Heart J. 17:(suppl F):1996;43-47
22. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, Mule JD, Vered Z, Lahiri A, and CHRISTMAS (Carvedilol hibernating reversible ischaemia trial: marker of success) investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003;362:14-21